A clinical trial update dated October 8, 2026 reports that a study titled "Thymalfasin for Immune Recovery in Adults With Sepsis" is currently recruiting participants. Thymalfasin is the pharmaceutical name for thymosin alpha-1, a peptide that remains classified as an unapproved research compound. The trial, registered as NCT07866118, is listed with a phase designation of not applicable, indicating it does not fall under the standard phased clinical trial structure. The study's recruiting status means that researchers are actively seeking eligible adult participants with sepsis to enroll at this time. No outcome measures, enrollment numbers, or results have been reported as part of this update. The trial update does not include any information about safety findings, efficacy signals, or preliminary data. This status change reflects only the current stage of the trial process, not any conclusions about the compound's effects in sepsis patients. Readers interested in the broader context of thymosin alpha-1 research and its regulatory status can consult the compound overview for additional background.
Trial Update: Thymalfasin Study in Sepsis Patients Now Recruiting
See the full thymosin alpha-1 overview
Source: https://clinicaltrials.gov/study/NCT07866118